ValuEngine upgraded shares of BeyondSpring (NASDAQ:BYSI) from a sell rating to a hold rating in a research note issued to investors on Wednesday, May 2nd.
Several other analysts have also recently issued reports on the company. Maxim Group reaffirmed a buy rating and set a $52.00 price objective on shares of BeyondSpring in a report on Wednesday, February 7th. HC Wainwright set a $60.00 price target on BeyondSpring and gave the company a buy rating in a report on Thursday, March 1st. Finally, Zacks Investment Research upgraded BeyondSpring from a sell rating to a hold rating in a report on Tuesday, January 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $49.60.
BeyondSpring opened at $27.61 on Wednesday, MarketBeat.com reports. BeyondSpring has a 52-week low of $27.55 and a 52-week high of $27.55.
BeyondSpring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.